1. Home
  2. GVH vs FEMY Comparison

GVH vs FEMY Comparison

Compare GVH & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globavend Holdings Limited

GVH

Globavend Holdings Limited

HOLD

Current Price

$0.99

Market Cap

10.7M

Sector

N/A

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$3.70

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GVH
FEMY
Founded
2016
2004
Country
Australia
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
12.0M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
GVH
FEMY
Price
$0.99
$3.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$80.00
$5.50
AVG Volume (30 Days)
1.1M
44.0K
Earning Date
02-17-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.71
EPS
N/A
N/A
Revenue
N/A
$2,293,313.00
Revenue This Year
$102,768.97
$105.16
Revenue Next Year
N/A
$200.23
P/E Ratio
$0.74
N/A
Revenue Growth
N/A
40.77
52 Week Low
$0.87
$0.29
52 Week High
$7.19
$6.29

Technical Indicators

Market Signals
Indicator
GVH
FEMY
Relative Strength Index (RSI) 28.78 53.59
Support Level N/A $3.50
Resistance Level $1.79 $4.78
Average True Range (ATR) 0.47 0.42
MACD -0.41 -0.08
Stochastic Oscillator 2.20 60.00

Price Performance

Historical Comparison
GVH
FEMY

About GVH Globavend Holdings Limited

Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: